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hnplantation of the TandemHeart Percutaneous Left 
Ventricular Assist Device 
James A. Magovern and David M. Lasorda 
M 'echanical circulatory suI)port is a very i)owerful .therai)y that simultaneously improves blood flow 
and reduces cardiac work. The beneficial effects of this 
technology were recently demonstrated by tile results of 
the REMATCH trial, which showed a large survival 
benefit for patients with heart failure who were treated 
with an iml)lantable left ventricular assist device 
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(LVAD). 1 Nonetheless, LVAD therapy typically re- 
quires a major surgical operation and tile use of expen- 
sive technology that limits tile therapy to a small group 
of highly selected individuals. 
Tile TandemHeart (Cardiac Assist Inc., Pittsburgh, 
PA) is a small centrihlgal blood pump that was origi- 
nally developed as a short-ternl implantable device 
called tile AB-180. 2-t The potential therapeutic range of 
this device was recently expanded by minor modifica- 
tions that allow percutaneous access for inflow and 
outflow to an externally located paracorporeal pinup, s
Tile device has been renamed the TandemHeart, and 
the percutaneous procedure has been termed percuta- 
neous transcptal ventricular assist. The technique for 
deployment of tile system is described in this article. 
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SURGICAL TECHNIQUE 
1 Tile photograph shows the TandemHeart pump, which is a small eentrifilgal mml ~ driven by an electromagnetic motor. 
On a mock loop, the device can flow up to  10 L/rain, but in the clinical setting, the average flow is 3 to 4 Idmin owing to 
limitations from cannula size. 
Tile photograldl shows tile pre-curved transeptal 
cannula (right), the obturator for the cannula (middle), 
and the 2-stage dilator (left) that is used to enlarge the 
transeptal puncture site. 
\ 
= 
\ 
\ 
/ 
/ 
)' 
, /  
/ 
/ 
Y 
j" 
/ 
114,  3~AGO','I~tN AND LtSOI|DA 
3 The 1)hotogral)h shows the needle, wire, 
dilators, and 15-F arterial cannula used to can- 
nulate the femoral artery. 
4 Tile photogral}h shows tile lmml } controller, which stands 
adjacent to the patient bed. Tile unit is small, compact, and 
transportable. It also has a built-in back-up unit for use in tile 
case of controller fiiilure. The controller egulates pump speed, 
the lubrication system, and alarm functions. Operation of the 
unit is quite simple, consisting of a dial to increase or decrease 
the revolutions per minute. 
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5 Tile schenlatic drawing shows tile unique fluid seal that distinguishes this punq) from other centrifugal pumps. Tile 
lulJrication line (yellow) delivers 10 lnL/h of hcparinized sterile water into tile lUmlll, which foats tile impeller on the rotor and 
provides a liquid seal between the upper and lower housing. The delivery of heparinizcd fluid also allows local anticoagulation 
within the I)Unql. 
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6 Placement of the transeptal cannula begins with access- 
ing tile right femoral vein percutaneonsly. Then a 0.032" 
J-tip guide~ire is advanced to the superior vena cava. A 
Mullins sheatlgcatheter is advanced over the wire. The 
guidewire is removed, and a Brockenbaugh transeptal needle 
is advanced through the catheter (not extending beyond the 
tip of tile catheter). Tile sheatldeatheter/needle are Imlled 
back into the right atrium until tile fossa ovale is engaged. 
Eehoeardiography is also helpfld in eonfirnfing engagement 
of the fossa with tile transeptal needle. (The drawing shows a 
4-chamber view of tile heart with tile transeptal needle push- 
ing tile fossa ovale toward the left atrium.) The needle fol- 
lowed by the catheter and sheath are advanced through tile 
fossa ovale into tile left atrium. Tile position in the left 
atrium can be confirmed by measuring pressure and inject- 
ing contrast (lye through tile sheath. After satisfactory 1)osi- 
tion has been demonstrated, tile transeptal needle and cath- 
eter are removed, leaving the sheath in the left atrium. Then, 
a long Toray wire is advanced through the sheath into the left 
atrium and the sheath is removed. 
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~" At this point, a looped wire is l,resent in the left atrium, which is shown in the drawiug. A graduated 2-stage dilator (14 
to 21-F) is then advanced over the wire to dilate the septal puncture site. Next, a 21-F venous caunula is imssed over the wire 
and positioned in the left atriuln. The arterial return canmda is inserted into the common femoral artery using the Sehlinger 
technique. Either the right or left side can be used. If a smaller eturn cannula is necessary because of concerns al,out distal 
leg ischemia, two 10-F cannulas can be inserted, one in each femoral artery (not shown). 
Comments  
The TandemHeart  has been used in over 100 patients as 
of January  2002. The procedures have been more rapid 
and less traumatic than open surgical LVAD implanta- 
tion. hnplant times have been less than 45 minutes, and 
pump flows of 3 to 4 L/nfin have been routinely achieved. 
Most patients lmve a detectable shunt at the atrial level 
after removal of tile cannula, lint it often seals spontanc- 
ously witlfiu 6 to 12 weeks. No patients have reqtfired 
surgical closure of an atrial septal defect. 
The intended use for tile device is in cases of acute 
heart fai lure, such as myocardial  infarction, dccom- 
pensated valvular heart  disease, or post-cardiotomy 
shock. The best success occurs when tile patient is 
bridged to definitive therapy,  such as revasculariza- 
tion, valve surgery, or an imlflantable LVAD. The 
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8 The drawing shows a patient ~dth the complete system in place. The transeptal cannula can 
be seen extending from the right femoral vein to the right atrium, and then entering the left 
atrium. The arterial cannula is also shown in the right femoral artery. The blood puml~ is 
attached with a Velcro mechanism to a circumferential bandage around the patient's tlfigh. 
average implant time has been 3 clays (range 1 to 14 
days), l)ut tile device can provide support for several 
weeks if clinically indicated. 
Mechanical circtdatory supl)ort is a very powerful ther- 
apy, but until recently, it has been restricted to a small 
number of patients because of the need for a major sur- 
gical procedure for imi)lantation. There are perlmps 200 
cardiac surgeons in the United States with extensive x- 
perience in LVAD implantation. Tllis is an insignificant 
fraction of the nmnber of physicians who deal with acute 
heart failure. For mechanical circulatory support to be- 
come a therapy that is available for all potential patients, 
more i)hysicians need to be involved, tile access procedure 
has to be simpler, and tile devices need to be less costly. 
Pereutaneous transeptal vcntricldar assist with the Tan- 
dcmHeart fltlfdls all these criteria. The system is commer- 
cially available in Europe and is ill a phase II Food & 
Drug Admhfistration trial ill the United States. It is hoped 
that tile TandemHeart will be available in the United 
States within 1 to 2 years. This will provide an important 
new tool for cardiac surgeons and intervcntional cardiol- 
o~sts to deal with acute heart failure. 
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